

Supporting Information

DDIT4 overexpression associates with poor prognosis in lung adenocarcinoma

Li Song^{a,b,†}, Zhiyao Chen^{a,†}, Menghua Zhang^a, Mingli Zhang^a, Xiaoyun Lu^c, Chunsun Li^{c,*} and Liyan Miao^{a,*}

^a Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China, 215006.

^b Department of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong 226361, Jiangsu, China

^c Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong 226361, Jiangsu, China

[†] These authors contributed equally to this work.

***Corresponding authors**

Liyan Miao, Chunsun Li

No. 188, Shi Zi Street, Suzhou, 215006, PR China

Tel.: (+86) 512-6797-2699; Fax: (+86)512-6797-2699

E-mail address: miaolysuzhou@163.com, miaoliyan@suda.edu.cn

Result of Kaplan Meyer curve revealed that LUAD patients with high DDIT4 expression had a significantly short progression-free survival than those with low DDIT4 expression ($P<0.01$).




Fig. S1. The relationship between the expression levels of DDIT4 and PFS in LUAD ($P<0.01$)

Supplemental Table 1. Characteristics of patients with non-small cell lung cancer

		Lung adenocarcinoma (n=89)
Age, median (range)		68 (38-87)
Sex (n, %)		
	Male	41 (46.1%)
	Female	48 (53.9%)
Smoking status (n, %)		
	Never smoker	66 (74.2%)
	Ever smoker	23 (25.8%)
Lymph node metastasis		
	N0	55 (61.8%)
	N1/N2/N3	34 (38.2%)
Stage		
	Stage I	34 (38.2%)
	Stage II	24 (27.0%)
	Stage III	27 (30.3%)
	Stage IV	4 (4.5%)